Bentsur Ron

Chairman & CEO, Director, 10% OwnerNuvectis Pharma, Inc. (NVCT) · full profile →Form 4 · filed Oct 6, 2023
Net Buying
Open-Market Buys
$35K
Open-Market Sells
$0
Net Open-Market Flow
$35K
Transactions
2
2 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Oct 5, 2023Buy(P)1K$11.09$16K3.2M
Oct 4, 2023Buy(P)2K$10.95$20K3.2M

Transaction Codes

P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001104659-23-107367) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

Build

Build on these Form 4 transactions

The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.